Mediators of meningitis: therapeutic implications.
Despite the availability of potent antibiotics, bacterial meningitis is still a major clinical problem. Mortality is high, and up to a third of survivors are left with neurologic sequelae that may range from mild behavioral disorders to mental retardation or deafness. New therapeutic approaches to meningeal inflammation, however, are reducing the neurologic risks.
Sáez-Llorens
X
X
University of Texas Southwestern Medical Center, Dallas.
McCracken
G H
GH
D000293:Adolescent; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000503:physiopathology*; D001812:Blood-Brain Barrier / Q000502:physiology; D001929:Brain Edema / Q000503:physiopathology; D002463:Cell Membrane Permeability; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D007375:Interleukin-1 / Q000378:metabolism; D008581:Meningitis / Q000188:drug therapy / Q000503:physiopathology*; D011817:Rabbits; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000900:Anti-Bacterial Agents; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D003907:Dexamethasone